Clark Capital Management Group, Inc.
Position in CPRX — Catalyst Pharmaceuticals, Inc.
CIK 1352187
PHILADELPHIA, PA
Position in CPRX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$14,080,417
+$5,566,032 QoQ
Shares Held
568,676
+44.9% QoQ
Ownership
0.465%
of shares outstanding
% of Portfolio
0.12%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2023
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CPRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Clark Capital Management Group, Inc. holds $130,946,596 across 6 Biotechnology names. CPRX ranks #3 (10.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RPRX |
Royalty Pharma plc
|
1,639,968 | $78,669,264 | |
| 2 | LGND |
Ligand Pharmaceuticals Inc
|
90,206 | $18,009,627 | |
| 3 | CPRX |
Catalyst Pharmaceuticals, Inc.
This page
|
568,676 | $14,080,417 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
214,102 | $13,837,412 | |
| 5 | EXEL |
Exelixis, Inc.
|
142,980 | $6,132,412 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
487 | $217,464 |
All Filings in CPRX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $14,080,417 | 568,676 | Shares | Sole | 2026-05-15 | |
| 2025-06-30 | $8,514,385 | 392,368 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $5,941,128 | 244,995 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $4,335,387 | 207,733 | Shares | Sole | 2025-02-14 | |
| 2023-12-31 | $2,922,552 | 173,858 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $2,327,116 | 199,069 | Shares | Sole | 2023-11-14 | |
| 2023-06-30 | $2,057,556 | 153,092 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $2,361,804 | 142,449 | Shares | Sole | 2023-05-15 | |
| No filing history on record for this holder in this stock. | ||||||